

For Research Use Only

Recombinant Human KIR3DL3 protein (rFc Tag)



Catalog Number: Eg4358

Basic Information

Species:
Human

Purity:
>90 %, SDS-PAGE

Tag:
rFc Tag

Technical Specifications

Purity:

>90 %, SDS-PAGE

Endotoxin Level:

<0.1 EU/μg protein, LAL method

Source:

HEK293-derived Human KIR3DL3 protein Gln26-Leu322 (Accession# Q8N743) with a rabbit IgG Fc tag at the C-terminus.

GeneID:

115653

Accession:

Q8N743

Predicted Molecular Mass:

58.3 kDa

SDS-PAGE:

60-70 kDa, reducing (R) conditions

Formulation:

Lyophilized from 0.22 μm filtered solution in PBS, pH 7.4. Normally 5% trehalose and 5% mannitol are added as protectants before lyophilization.

Biological Activity

Not tested

Storage and Shipping

Storage:

It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.

- Until expiry date, -20°C to -80°C as lyophilized proteins.
- 3 months, -20°C to -80°C under sterile conditions after reconstitution.

Shipping:

The product is shipped at ambient temperature. Upon receipt, store it immediately at the recommended temperature.

Reconstitution

Briefly centrifuge the tube before opening. Reconstitute at 0.1-0.5 mg/mL in sterile water.

Background

KIR3DL3, a member of the killer cell immunoglobulin-like receptor (KIR) family, is an inhibitory receptor primarily expressed on natural killer (NK) cells and a subset of CD8+ T cells. It plays a role in immune regulation by recognizing specific HLA class I molecules, contributing to the balance between immune activation and inhibition. Recent research has identified KIR3DL3 as an inhibitory receptor for HHLA2, a B7 family ligand, suggesting its involvement in immune checkpoint pathways. KIR3DL3's interaction with HHLA2 can recruit SHP-1 and SHP-2 to attenuate signaling pathways such as Vav1, ERK1/2, AKT, and NF-κB, thereby inhibiting CD8+ T and NK cell functions. It is expressed on immune cells infiltrating HHLA2+ tumors from the human kidney, lung, gallbladder, and stomach, suggesting its potential as a therapeutic target for cancer.

References

1. Trundley AE, et al. (2006). Immunogenetics. 57(12):904-916.
2. Wei Y, et al. (2021). Sci Immunol. 6(61):eabf9792.
3. Campbell KS. (2021). Cancer Immunol Res. 9(2):128.
4. Li Y, et al. (2023). J Adv Res. 47:137-150.

Synonyms


KIR3DL3, CD158Z, KIR3DL7, KIR44, KIRC1

For technical support and original validation data for this product please contact

T: 1 (888) 4PTGLAB (1-888-478-4522) (toll free in USA), or 1(312) 455-8498 (outside USA) E: proteintech@ptglab.com
W: ptglab.com

This product is exclusively available under Proteintech Group brand and is not available to purchase from any other manufacturer.

Selected Validation Data



Purity of Recombinant Human KIR3DL3 was determined by SDS-PAGE. The protein was resolved in an SDS-PAGE in reducing (R) and non-reducing (NR) conditions and stained using Coomassie blue.